LFWD Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 2.06%, SMA50 -10.42%, SMA200 -25.97%). The stock’s 14-day RSI is 49.39 (neutral), while the ATR of 0.71 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.72% below its high and over 56.28% above its low. Average 10-day trading volume of 36.75 thousand shares is significantly above the 3-month average of 12.24 thousand, indicating heightened recent market interest.

Lifeward Ltd. has 15.60 million shares outstanding. The public float is 15.42 million shares, elevated short interest at 9.67% of float. This equals 1.48 million shares. The short ratio is 2.19 days. Institutional investors hold 2.95% of the float. Insiders own 2.07%. Lind Global Fund II LP holds 858.00 thousand shares, Jasinski Lawrence J has 98.73 thousand shares and Swinford Michael has 65.04 thousand shares.

Lifeward Ltd. generated EPS of -$35.73 over the past year. Five-year average earnings growth is 29.33%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.50. The high target offers 25.79% upside. The low target suggests -43.4% downside. The mean target is $7.25. This offers -8.81% upside. Lifeward Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 15, 2026, missed forecasts by 165.25%. The prior quarter beat by 328.57%. Over the last six quarters, Apple has recorded several small beats. These include 90.0% in March 07, 2025.

Lifeward Ltd. (NASDAQ:LFWD) shares are up 25.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lifeward Ltd. trading at a premium to the broader market with a P/E of -0.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.00, suggesting 13.21% upside. Our AI forecast model points to short-term strength (11.19% over two weeks), a medium-term fall (-76.6% over three months), and a longer-term gain (1.13% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lifeward Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.19%, with price expected at $8.84 by July 27, 2026, within a range of $8.28 to $9.37 3-Month Outlook: Projected fall of -76.6%, reaching $1.86 by October 08, 2026, with a range of $1.24 to $2.41. 1-Year Outlook: Projected gain of 1.13%, with price at $8.04 by July 13, 2027, within a range of $2.10 to $7.13.

Lifeward Ltd. (NASDAQ:LFWD) closed at $7.95 USD, losing -$0.43 (-5.19%) from the previous close of $8.38. The stock is currently mid-range between its 52-week high and low $4.14 and $10.56. With a market capitalization of about $12.81 million, Lifeward Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.37). Key stats such as the average daily volume over the past year has been around 11.97 thousand shares, in line with its 52-week average. Headquartered in Yokneam Illit, MA, Lifeward Ltd. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO William Mark Grant, the company employs approximately 81 people and listed since September 12, 2014. Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons.

Lifeward Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.89. This means the shares are trading below this model’s fair value.

Lifeward Ltd. trades at a P/E ratio of -0.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.61 and a price-to-book ratio of 2.02 suggesting the stock is closer to book value. The P/FCF stands at -0.85, also above market averages.